Consumer dissatisfaction with drug prices is not news, but it has not yet been addressed by competition or Congress. Consumers are elevating the issue to one of national importance, and the biopharmaceutical industry is beginning to pay attention, because they dread what is coming next – people from the government who are here to help. […]
The CREATES Act, if enacted, would remove industry entry barriers, encourage market competition, bring lower cost drugs to market, and benefit patients. The following is the coalition letter send to the Senate Judiciary Committee (click here for a printable version): ————– July 12, 2016 The Honorable Chuck Grassley The Honorable Patrick J. Leahy Committee on the Judiciary United States Senate 224 […]
The recent approval of the first biosimilar drug by the FDA will mark the beginning of competition for a class of lifesaving medicines in the U.S., after nearly a decade of availability in Europe and elsewhere. This ConsumerGram will explore how the pending introduction of competition for biologic drugs will lead to immense consumer benefits, both […]
In India, patent theft seems to be in style. Recently, Novartis’ Glivec, a cancer fighting drug was denied patent status in India. India claims Glivec is insufficiently novel to deserve a patent. The claim is at odds with Glivec’s patent protections in large and low income countries that play by the rules, including China. In […]
At the 2nd World Congress on Bioavaialability & Bioequivalence 2011- Pharmaceuticals R&D Summit, “Economics of Biosimilars” June 7, 2011.
Genetic Engineering & Biotechnology News quotes ACI Expert and Weidener University Economics Professor Joseph Fuhr, Jr at the following link. The article notes the expected explosive growth of biosimilar sand follow-on biologics, but nonetheless expects competitors to proceed cautiously.